The treatments given to President Donald Trump for his case of COVID-19 are also being used in Sioux Falls patients.
- Real Estate
- Food & Drink
“SAB is a very different company today than we were at the beginning of the year.” With unprecedented growth and a one-of-a-kind treatment for COVID-19, SAB Biotherapeutics is just getting started.
Sioux Falls-based SAB Biotherapeutics has started testing in a human patient for its therapeutic specifically developed for the virus that causes COVID-19.
Sioux Falls-based SAB Biotherapeutics has received an additional $35.6 million in government funding, plus $14 million in series B funding that includes a new investor – global health care leader Merck.
Sioux Falls-based SAB Biotherapeutics has confirmed that its treatment in development specifically for the virus that causes COVID-19 has produced antibodies that neutralized the virus in a way that’s four times as potent as using plasma from recovered patients.
Sioux Falls-based SAB Biotherapeutics is joining with global biotherapeutics leader CSL Behring to rapidly develop SAB-185, a COVID-19 therapeutic candidate on track for clinical evaluation by early summer.